CD44 and neoplasm: Several strategies, including CD44-targeting monoclonal antibodies and inhibitory peptides, are in various phases of preclinical and clinical development to deal with chemoresistance, tumor regrowth and metastases of CD44-overexpressing malignancies [11,54,70].